The data presented herein relates to the article entitled "Norfluoxetine and venlafaxine in zebrafish larvae: single and combined toxicity of two pharmaceutical products relevant for risk assessment" [1]. Recent studies have shown the occurrence of active metabolites of human and veterinary pharmaceuticals in surface and wastewaters. Besides their biological activity, some are predicted to interact with the same molecular targets of their parental compounds, thus showing the potential to elicit detrimental effects on animals. Despite this, limited investigation on their effects on aquatic animals has been done. Genomic material resulting from zebrafish (Danio rerio) larvae exposed to the psychoactive compounds norfluoxetine (main fluoxetine metabolite), venlafaxine, or their mixture was collected for gene expression analysis of a determined pool of genes potentially involved in their mode-of-action and metabolism. Molecular parameters are a cost-effective and reliable way to understand modes-of-action and the potential risk of micropollutants, such as pharmaceutical products, in non-target organisms. Moreover, gene expression patterns can provide crucial complementary information to improve risk assessment, and monitoring of affected systems. The data reported in this article was used to depict the effects of single or combined exposure to norfluoxetine and venlafaxine and identify biomarkers of exposure to these compounds of interest to diagnose exposure and routine monitoring.
Keywords: Active metabolite; Gene expression; Mixture toxicity; Monoamine receptors and transporters; SNRI; SSRI.
© 2020 The Authors. Published by Elsevier Inc.